Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma (Q38155039)

29 August 2017

title

Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma (English)

1 reference

29 August 2017

1 reference

D Atanackovic

1

1 reference

29 August 2017

T Luetkens

series ordinal

2

1 reference

29 August 2017

N Kröger

series ordinal

3

1 reference

29 August 2017

publication date

23 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

28

1 reference

29 August 2017

issue

5

1 reference

29 August 2017

page(s)

993-1000

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2013.310

29 August 2017

exact match

0 references

cites work

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Proteasome inhibitors in multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Lenalidomide in multiple myeloma: Current status and future potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Review of 1027 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Infections in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Chemokines in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Immunoregulatory mechanisms in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Th1/Th2 cells in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Regulatory T cells and mechanisms of immune system control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Dysfunctional T regulatory cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

CD200 is a new prognostic factor in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Expression of programmed death 1 ligands by murine T cells and APC

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Malignant B cells induce the conversion of CD4+CD25- T cells to regulatory T cells in B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Lenalidomide enhances anti-myeloma cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.310

21 January 2018

1 reference

12 December 2020

Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance

1 reference

12 December 2020

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

2 references

12 December 2020

https://api.crossref.org/works/10.1038%2FLEU.2013.310

7 January 2021

inferred from DOI database lookup

Causes of death in cases of lymphoma, myeloma and Hodgkin disease. Study of 218 cases

1 reference

12 December 2020

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma

1 reference

12 December 2020

Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation

1 reference

12 December 2020

Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells

1 reference

12 December 2020

Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis

1 reference

12 December 2020

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

1 reference

12 December 2020

Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion

1 reference

12 December 2020

Graft-versus-myeloma effect: proof of principle

1 reference

12 December 2020

EblacZ tumor dormancy in bone marrow and lymph nodes: active control of proliferating tumor cells by CD8+ immune T cells

1 reference

12 December 2020

Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia

1 reference

12 December 2020

Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells.

1 reference

12 December 2020

Multiple myeloma: review of 869 cases

1 reference

12 December 2020

The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma

1 reference

12 December 2020

Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma.

1 reference

12 December 2020

Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors

1 reference

12 December 2020

The use of intravenous immune globulin in multiple myeloma

1 reference

12 December 2020

Influence of treatment and response status on infection risk in multiple myeloma

1 reference

12 December 2020

Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy

1 reference

12 December 2020

Donor leukocyte infusions for multiple myeloma

1 reference

12 December 2020

Bone marrow T-cell subsets in patients with monoclonal gammopathies: correlation with clinical stage and disease status

1 reference

12 December 2020

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

1 reference

12 December 2020

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

1 reference

12 December 2020

Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients

1 reference

12 December 2020

Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells

1 reference

12 December 2020

Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes

1 reference

12 December 2020

Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections

1 reference

12 December 2020

Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM

1 reference

12 December 2020

Multiple myeloma: increasing evidence for a multistep transformation process

1 reference

12 December 2020

Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up

1 reference

12 December 2020

Homing mechanisms of myeloma cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2013.310

1 reference

Dimensions Publication ID

29 August 2017

1051567220

0 references

1 reference